title: Biomarker discovery in human SLE nephritis.
abstract: The treatment of systemic lupus erythematosus (SLE) nephritis, while effective, is associated with significant morbidity and mortality. These side effects could be mitigated if the onset, severity, and response of renal flare could be predicted, and therapy modified accordingly. In this review, an approach to derive prediction equations of SLE nephritis flare is discussed. Integral to generating such prediction equations is the identification of biomarkers of lupus nephritis that can serve as input variables for modeling flare. The use of urine as a source of SLE nephritis biomarkers is described, and the results of urine biomarker discovery studies using candidate and proteomic approaches are presented.
authors.affiliation: Division of Nephrology, Ohio State University College of Medicine, and Columbus Children's Hospital Research Center 43210, USA. Rovin.1@osu.edu
authors.forename: Brad H
authors.initials: BH
authors.lastname: Rovin
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Birmingham
authors.forename: Haikady N
authors.initials: HN
authors.lastname: Nagaraja
authors.forename: C Yung
authors.initials: CY
authors.lastname: Yu
authors.forename: Lee A
authors.initials: LA
authors.lastname: Hebert
mesh_terms: D052242:Adiponectin / Q000652:urine; D015415:Biomarkers / Q000652:urine*; D018932:Chemokine CCL2 / Q000652:urine; D006801:Humans; D008181:Lupus Nephritis / Q000473:pathology / Q000652:urine*; D011237:Predictive Value of Tests; D040901:Proteomics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D052242:Adiponectin; D015415:Biomarkers; C111835:CCL2 protein, human; D018932:Chemokine CCL2